Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page
- Check4 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, indicating a minor build/template update that does not modify study content.SummaryDifference0.1%

- Check12 days agoChange DetectedThe page now shows revision v3.6.2 instead of v3.6.0, indicating a newer build of the site. This update records the release version displayed for the page.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe study record now shows recruitment has ended with a note 'No longer looking for participants.' New help sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study' were added, and the Intervention/Treatment label formatting was updated.SummaryDifference0.6%

- Check33 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, indicating a small, non-substantive update to the page.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4, indicating a backend/template update to the page without changing the displayed study information.SummaryDifference0.1%

- Check69 days agoChange DetectedThe study record was updated to add Janssen Scientific Affairs, LLC as a collaborator and remove the National Cancer Institute (NCI); recent timestamps indicate that the record has been refreshed.SummaryDifference0.3%

Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.